RHOEN-KLINIK.UNSP.ADR 1/2 (F:RHKU) — Stock Price
RHOEN-KLINIK.UNSP.ADR 1/2 (F:RHKU) is currently trading at €5.80 EUR, up 3.57% today. Over the past 52 weeks, shares have ranged between €5.40 and €7.65. This page tracks RHOEN-KLINIK.UNSP.ADR 1/2's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see RHOEN-KLINIK.UNSP.ADR 1/2 (RHKU) cash conversion ratio.
RHOEN-KLINIK.UNSP.ADR 1/2 (RHKU) Stock Price Chart — Daily History & Trading Volume
The chart below tracks RHOEN-KLINIK.UNSP.ADR 1/2's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
RHOEN-KLINIK.UNSP.ADR 1/2 Income Statement — Revenue, Profit & Earnings by Year
RHOEN-KLINIK.UNSP.ADR 1/2's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €1.60 Billion | €1.46 Billion | €1.45 Billion | €1.40 Billion |
| Cost of Revenue | €1.42 Billion | €1.32 Billion | €1.25 Billion | €1.20 Billion |
| Gross Profit | €171.82 Million | €148.81 Million | €198.92 Million | €197.62 Million |
| Research & Development | — | — | — | — |
| SG&A | €69.40 Million | €70.30 Million | €74.30 Million | €63.10 Million |
| Total Operating Expenses | €1.56 Billion | €1.43 Billion | €1.41 Billion | €1.37 Billion |
| Operating Income | €37.50 Million | €29.63 Million | €34.49 Million | €29.67 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €3.40 Million | €3.70 Million | €4.10 Million | €3.20 Million |
| Income Before Tax | €56.20 Million | €47.73 Million | €33.63 Million | €27.36 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €43.35 Million | €38.71 Million | €25.14 Million | €28.30 Million |
RHOEN-KLINIK.UNSP.ADR 1/2 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes RHOEN-KLINIK.UNSP.ADR 1/2's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €1.86 Billion | €1.77 Billion | €1.70 Billion | €1.67 Billion |
| Total Current Assets | €904.11 Million | €789.21 Million | €688.61 Million | €611.08 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | €146.80 Million | €146.80 Million | €227.60 Million | €173.40 Million |
| Net Receivables | €226.90 Million | €229.53 Million | €228.60 Million | €212.86 Million |
| Inventory | €37.46 Million | €34.21 Million | €33.32 Million | €33.12 Million |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | €165.40 Million | €165.40 Million | €165.50 Million | €165.20 Million |
| Total Liabilities | €530.51 Million | €490.30 Million | €453.51 Million | €440.82 Million |
| Total Current Liabilities | €404.85 Million | €335.47 Million | €291.08 Million | €273.31 Million |
| Long-term Debt | €110.90 Million | €141.80 Million | €141.70 Million | €148.60 Million |
| Net Debt | — | — | €72.37 Million | €23.28 Million |
| Total Stockholder Equity | €1.30 Billion | €1.25 Billion | €1.22 Billion | €1.20 Billion |
| Retained Earnings | — | — | — | — |
RHOEN-KLINIK.UNSP.ADR 1/2 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how RHOEN-KLINIK.UNSP.ADR 1/2 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | €127.60 Million | €109.00 Million | €60.30 Million | €97.50 Million |
| Capital Expenditures | €70.40 Million | €62.80 Million | €58.20 Million | €77.80 Million |
| Free Cash Flow | €57.20 Million | €46.20 Million | €2.10 Million | €19.70 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | — | — | — | — |
| Dividends Paid | — | €10.00 Million | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | €62.60 Million | €65.60 Million | €69.60 Million | €70.20 Million |
| Change in Cash | €73.90 Million | €128.70 Million | €-49.00 Million | €35.30 Million |
RHOEN-KLINIK.UNSP.ADR 1/2 Earnings History — EPS Actual vs. Analyst Estimates
Track RHOEN-KLINIK.UNSP.ADR 1/2's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 06, 2026 | — | — | — |
| Mar 25, 2026 | — | — | — |
| Nov 06, 2025 | — | — | — |
| Aug 07, 2025 | — | — | — |
| May 08, 2025 | — | — | — |
| Mar 26, 2025 | — | — | — |
| Nov 07, 2024 | — | — | — |